Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.735
-0.040 (-1.44%)
At close: Jul 10, 2026, 4:00 PM EDT
2.690
-0.045 (-1.65%)
After-hours: Jul 10, 2026, 6:16 PM EDT
Xenetic Biosciences Employees
Xenetic Biosciences had 2 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,595,037
Profits / Employee
-$1,117,051
Market Cap
6.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2024 | 2 | -2 | -50.00% | 2 | 0 |
| Dec 31, 2023 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2022 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2021 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| AIM ImmunoTech | 21 |
| Purple Biotech | 10 |
| XTL Biopharmaceuticals | 10 |
| Adial Pharmaceuticals | 5 |
| Acurx Pharmaceuticals | 4 |
| Silo Pharma | 3 |
| Addex Therapeutics | 3 |
XBIO News
- 5 weeks ago - Xenetic partner PeriNess receives Israeli MOH approval for DNase I study - TheFly
- 5 weeks ago - Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma - Accesswire
- 5 weeks ago - Xenetic announces preclinical data on DNase I at ASCO - TheFly
- 5 weeks ago - Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - Accesswire
- 7 weeks ago - Xenetic Biosciences Slides: Investor presentation - Filings
- 2 months ago - Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform - Accesswire
- 2 months ago - Xenetic Biosciences Quarterly report: Q1 2026 - Filings
- 2 months ago - Xenetic Biosciences Earnings release: Q1 2026 - Filings